Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

United Therapeutics (UTHR) Gains from Sales and Divestitures (2018 - 2020)

United Therapeutics' Gains from Sales and Divestitures history spans 3 years, with the latest figure at $104818.0 for Q1 2020.

  • For Q1 2020, Gains from Sales and Divestitures rose 127.73% year-over-year to $104818.0; the TTM value through Mar 2020 reached $104818.0, up 127.73%, while the annual FY2019 figure was $74324.0, 290.13% up from the prior year.
  • Gains from Sales and Divestitures for Q1 2020 was $104818.0 at United Therapeutics, up from $74324.0 in the prior quarter.
  • Across five years, Gains from Sales and Divestitures topped out at $104818.0 in Q1 2020 and bottomed at $17820.0 in Q2 2018.
  • The 3-year median for Gains from Sales and Divestitures is $55192.0 (2019), against an average of $51762.5.
  • The largest annual shift saw Gains from Sales and Divestitures soared 290.13% in 2019 before it surged 127.73% in 2020.
  • A 3-year view of Gains from Sales and Divestitures shows it stood at $19051.0 in 2018, then skyrocketed by 290.13% to $74324.0 in 2019, then skyrocketed by 41.03% to $104818.0 in 2020.
  • Per Business Quant, the three most recent readings for UTHR's Gains from Sales and Divestitures are $104818.0 (Q1 2020), $74324.0 (Q4 2019), and $69761.0 (Q3 2019).